Semaglutide / working resource

Study reading worksheet

Separate a reported result from the question the study was designed to answer.

Start with the product-specific question

Wegovy, Ozempic and Rybelsus

An accessible treatment-decision site with precise product distinctions. What should I know about wegovy, ozempic and rybelsus: product and indication map?

STEP1 randomized 1961 adults without diabetes to subcutaneous 2.4 mg semaglutide or placebo plus lifestyle support for 68 weeks.
Read the original record ↗

Open the Semaglutide library ↗

Write the question before the result.

A Semaglutide headline may describe an animal experiment, an uncontrolled observation or a randomized human trial. Those designs answer different questions. Complete the record before deciding whether a result applies to a product.

Document title and original URLExact molecule, formulation and route studiedStudy design and number of participants or samplesPopulation, condition and inclusion criteriaComparison or control groupPrimary endpoint and follow-up period

Keep the result attached to its boundary.

Actual result, units and uncertainty intervalWhich analysis or estimand produced this number?Was this the primary endpoint or a subgroup finding?Adverse events and missing or incomplete follow-upFunding, conflicts, correction or later publicationWhat does this study leave unanswered for this product?

When there is no human comparison group or no relevant clinical endpoint, record that explicitly. A mechanism, biomarker or plausible explanation does not become a demonstrated patient benefit.

These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.

Explore all six resources ↗